Eric Dube, Travere CEO
September 16, 2021 08:30 AM EDT
Deals

For­mer Shkre­li com­pa­ny Tra­vere lands li­cens­ing deal with Vi­for on kid­ney drug

Paul Schloesser

Associate Editor

Just a month ago, the biotech for­mer­ly owned by con­vict­ed drug ex­ec Mar­tin Shkre­li saw promis­ing da­ta re­lat­ed to its kid­ney drug sparsen­tan from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times